Baxter International Inc reaches 20-day high amid market strength
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 06 Jan 26
Source: Coinmarketcap
Baxter International Inc's stock rose by 3.02% during regular trading, reaching a 20-day high. This positive movement aligns with broader market strength, as the Nasdaq-100 is up 0.42% and the S&P 500 has gained 0.20%.
The stock's increase is attributed to broad market strength, which has positively influenced investor sentiment. The overall market performance has provided a favorable backdrop for Baxter, contributing to its upward price movement.
Investors are optimistic about Baxter's future prospects, and the stock's performance reflects a strong alignment with the current market trends.
Analyst Views on BAX
Wall Street analysts forecast BAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BAX is 21.73 USD with a low forecast of 15.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
2 Buy
9 Hold
1 Sell
Hold
Current: 19.730
Low
15.00
Averages
21.73
High
30.00
Current: 19.730
Low
15.00
Averages
21.73
High
30.00
About BAX
Baxter International Inc. is a global medtech company. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of its sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. It provides a portfolio of diagnostic, critical care, nutrition, hospital and surgical products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
